Cooperative Agreement UG1CA189971

This Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research federal grant program (CFDA 93.395), provides $113,202 to support research capacity building efforts by Dr. Elie Dib at the Michigan Cancer Research Consortium (MCRC). The key products and services to be delivered through this award include: Contributing to MCRC initiatives aimed at increasing the rate of clinical trials enrollment by minority and underserved populations. Launching safety...

The University of Michigan will provide Phase 1/2 assessment in kidney cancer under a $1.4 million cooperative agreement award from the Department of the Army Medical Command. The three-year award, issued on September 15, 2021 under the Military Medical Research and Development program, will support the university's efforts to investigate medical solutions for the battlefield and transform military and public health through innovative biomedical research. As part of the CFDA 12.420 program,...

This federal Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $159,803 to the Regents of the University of Michigan to incorporate emerging genomic, transcriptomic, epigenomic, and proteomic technologies for the analysis of advanced, rare, and pediatric cancers. The project aims to translate these new analytical approaches into clinically actionable information through the development of reportable test results in the...

This $1,248,000 Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program will support the "RARE-CANCER COMMONS: A HUB FOR ACCELERATING INDIVIDUALIZED RARE CANCER THERAPY THROUGH INTEGRATION OF SINGLE-CELL AND CLINICAL GENOMICS DATA" research initiative at the University of Michigan. The project, running from November 1, 2024 to October 31, 2027, will leverage the University's extensive research capabilities to...

The University of Michigan received a $925,834 Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program. The grant will fund research into CDK12 as a context-specific tumorigenesis regulator and novel therapeutic target in castration-resistant prostate cancer. The research will be performed in Ann Arbor, Michigan over a three-year period from September 2021 through August 2024. Through the support of basic,...

The University of Michigan will receive $546,000 from the Department of the Army Medical Command under a Project Grant award to model virus-associated Merkel cell carcinoma in mice using viral DNA regulatory sequences from September 1, 2022 to August 31, 2025. This award is funded through the Military Medical Research and Development program (CFDA 12.420), which supports basic, applied, and advanced biomedical research to transform military and public health care through innovative medical...

The University of Michigan will receive $782,729 from the Department of the Army Medical Command under a Project Grant award through the Military Medical Research and Development program (CFDA 12.420) to improve outcomes for women with ovarian cancer. The four-year award beginning September 1, 2022 will support research to transform healthcare for Service Members and the public through innovative medical solutions for the battlefield and investigation of solutions for ovarian cancer. The...

This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $458,698 to the Regents of the University of Michigan to conduct research aimed at understanding the fundamental biological mechanisms underlying acute myeloid leukemia (AML) relapse. The research will focus on identifying novel gene drivers that confer therapy resistance and contribute to the competitive regrowth of leukemic cells after initial treatment, which is a major barrier...

This Project Grant award from the National Cancer Institute (CFDA 93.396, Cancer Biology Research) aims to investigate key transcriptional regulators that drive prostate cancer lineage plasticity, which can lead to more lethal cancer subtypes. The $509,246 award to the Regents of the University of Michigan will fund a 5-year research project to: 1) determine how these transcriptional regulators modulate prostate cancer cell differentiation and hallmarks, 2) understand how the regulators are...

This Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program provides $1,100,747.00 to the Regents of the University of Michigan to conduct research on "PROTEIN ENGINEERING OF ANTIBODY-DRUG CONJUGATES TO COORDINATE THE INNATE AND ADAPTIVE IMMUNE SYSTEMS FOR CURATIVE RESPONSES." The research aims to transform healthcare for military service members, veterans, and the broader public by advancing innovative biomedical...